Sulindac sodium
Based on 1 publication(s) in Google Scholar
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 63804-15-9
- 分子式: C20H16FNaO3S
- 分子量:378.39
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
Sulindac (MK-231) (500 μM, 48 h) sodium is effective in preventing TGF-β1-induced EMT, as indicated by upregulation of the epithelial marker, E-cadherin, and downregulation of mesenchymal markers and transcription factors[1].
Sulindac sodium (500 μM, 48 h) can inhibit TGF-β1-enhanced migration and invasion of A549 cells[1].
Sulindac sodium (500 μM, 48 h) enhances the reversal of TGF-β1-induced EMT by sulindac (sodium) and SIRT1 upregulation promoted TGF-β1-induced EMT[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells
-
Concentration:500 μM
-
Incubation Time:48 h
-
Result:Inhibit transforming growth factor (TGF)-β1-induced epithelial-mesenchymal transition in A549 cells.
-
Cell Line:A549 cells
-
Concentration:500 μM
-
Incubation Time:48 h
-
Result:Reversed SIRT-1 expression by TGF-β1 and inhibited the TGF-β1-induced cadherin switch.
-
Cell Line:A549 cells
-
Concentration:500 μM
-
Incubation Time:48 h
-
Result:Inhibited migration, decreased resistance co-treatment with TGF-β1.
-
Cell Line:A549 cells
-
Concentration:500 μM
-
Incubation Time:40 h; 48 h
-
Result:Could effectively inhibit the TGF- β1-induced increase in invasion by lung cancer cells.
体内実験
Sulindac sodium (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) can downregulate PD-L1 by blocking NF-κB signaling, which in turn led to a decrease in exosomal P[2].
Sulindac sodium (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) leads to increased availability of PD-L1 Ab by downregulating PD-L1 in combination therapy[2].
Sulindac sodium has not a systemic inhibitory effect on prostaglandin E2 (PGE2) in low-dose does[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CT26 syngeneic mouse tumor model[2]
-
Dosage:15 mg/kg; 7.5 mg/kg
-
Administration:15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)
-
Result:Downregulated PD-L1 through the blockade of NF-κB signaling and modulate the response of pMMR CRC to anti-PD-L1 immunotherapy.
-
Animal Model:CT26 syngeneic mouse tumor model[2]
-
Dosage:15 mg/kg; 7.5 mg/kg
-
Administration:15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)
-
Result:Downregulated PD-L1 through the blockade of NF-κB signaling and modulate the response of pMMR CRC to anti-PD-L1 immunotherapy.
Cound effectively inhibit PD-L1 with no significant systematic toxicity.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 63804-15-9
-
分子量 378.39
-
分子式 C20H16FNaO3S
-
SMILES
O=C(CC(C1=C2C=CC(F)=C1)=C(/C2=C/C3=CC=C(C=C3)S(C)=O)C)O[Na]
-
別名
MK-231 sodium
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
bioRxiv
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG. [Abstract]2026 Apr 18:2026.04.17.719256. PMID: 42039650
純度とドキュメンテーション
参考文献
[1]. Byong-Ki Cha, et al. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget. 2016 Aug 30;7(35):57213-57227. [Content Brief]
[2]. Bin Yi, et al. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy. Mol Cancer Ther. 2021 Jul;20(7):1295-1304. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- Sulindac
- 63804-15-9
- MK-231
- MK231
- MK 231
- NF-κB
- PD-1/PD-L1
- Nuclear factor-κB
- Nuclear factor-kappaB
- PD-1/Programmed death-ligand 1
- oral
- nonsteroidal
- anti-inflammatory
- immunomodulatory agent
- FDA
- NSAID
- colorectal cancer (CRC)
- pMMR
- TGF-β1
- epithelial-mesenchymal transition (EMT)
- SIRT1
- lung cancer
- migration
- invasion
- Inhibitor
- inhibitor
- inhibit